Patient-derived xenograft (PDX) models in basic and translational breast cancer research

Dobrolecki, L. E. and Airhart, S. D. and Alferez, D. G. and Aparicio, S. and Behbod, F. and Bentires-Alj, M. and Brisken, C. and Bult, C. J. and Cai, S. and Clarke, R. B. and Dowst, H. and Ellis, M. J. and Gonzalez-Suarez, E. and Iggo, R. D. and Kabos, P. and Li, S. and Lindeman, G. J. and Marangoni, E. and McCoy, A. and Meric-Bernstam, F. and Piwnica-Worms, H. and Poupon, M. F. and Reis-Filho, J. and Sartorius, C. A. and Scabia, V. and Sflomos, G. and Tu, Y. and Vaillant, F. and Visvader, J. E. and Welm, A. and Wicha, M. S. and Lewis, M. T.. (2016) Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer and Metastasis Reviews, 35 (4). pp. 547-573.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/61363/

Downloads: Statistics Overview


Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting long-established traditional cell lines as preferred models for conducting basic and translational preclinical research. In breast cancer, to complement the now curated collection of approximately 45 long-established human breast cancer cell lines, a newly formed consortium of academic laboratories, currently from Europe, Australia, and North America, herein summarizes data on over 500 stably transplantable PDX models representing all three clinical subtypes of breast cancer (ER+, HER2+, and "Triple-negative" (TNBC)). Many of these models are well-characterized with respect to genomic, transcriptomic, and proteomic features, metastatic behavior, and treatment response to a variety of standard-of-care and experimental therapeutics. These stably transplantable PDX lines are generally available for dissemination to laboratories conducting translational research, and contact information for each collection is provided. This review summarizes current experiences related to PDX generation across participating groups, efforts to develop data standards for annotation and dissemination of patient clinical information that does not compromise patient privacy, efforts to develop complementary data standards for annotation of PDX characteristics and biology, and progress toward "credentialing" of PDX models as surrogates to represent individual patients for use in preclinical and co-clinical translational research. In addition, this review highlights important unresolved questions, as well as current limitations, that have hampered more efficient generation of PDX lines and more rapid adoption of PDX use in translational breast cancer research.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Tumor Heterogeneity Metastasis and Resistance (Bentires-Alj)
UniBasel Contributors:Bentires-Alj, Mohamed
Item Type:Article, refereed
Article Subtype:Further Journal Contribution
Note:Publication type according to Uni Basel Research Database: Journal item
Related URLs:
Identification Number:
Last Modified:05 Mar 2019 18:42
Deposited On:05 Mar 2019 18:42

Repository Staff Only: item control page